498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial

Authors :: Nasca, V.
Raimondi, A.
Palermo, F.
Morano, F.
Bergamo, F.
Foltran, L.
Spallanzani, A.
Brunetti, O.
Spada, D.
Tamberi, S.
Antonuzzo, L.
Cella, C.A.
Avallone, A.
Bencardino, K.
Fornaro, L.
Di Donato, S.
Strippoli, A.
Puccini, A.
Tamburini, E.
Pietrantonio, F.
Source :: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS198-S199. 2p.
Publication Year :: 2024

Subjects :: *STOMACH cancer
*CANCER patients
*TRASTUZUMAB
*ESOPHAGEAL cancer
*CANCER chemotherapy
*BIOPSY

Full Text Access

Tools